Identification of activators for the M2 isoform of human pyruvate kinase
- PMID: 21433354
- Bookshelf ID: NBK47338
Identification of activators for the M2 isoform of human pyruvate kinase
Excerpt
The expression of human pyruvate kinase M2 (hPK-M2) in cancer cells appears to be critical for tumor cell growth and proliferation in vivo. Because the PK-M2 isoform is expressed in all cancer cells studied, it represents a target for drug development that could potentially enable tumor cells to return to a normal state of metabolism. If this novel strategy for targeting malignancy were successful, it would be applicable to diverse types of cancer. The probes ML083 (CID-650361) and ML082 (CID-654376) are members of a series of highly specific allosteric activators for the tumor-specific isoform of human pyruvate kinase (M2 isoform). Both probes affect the cooperativity of phosphoenolpyruvate (PEP) binding with little effect on adenosine diphosphate (ADP) binding in a manner similar to FBP.
Sections
Similar articles
-
Identification of activators for the M2 isoform of human pyruvate kinase Version 3.2009 Sep 1 [updated 2011 Mar 3]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. 2009 Sep 1 [updated 2011 Mar 3]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. PMID: 21735594 Free Books & Documents. Review.
-
Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation.Int J Cancer. 2008 Jul 15;123(2):312-321. doi: 10.1002/ijc.23512. Int J Cancer. 2008. PMID: 18425820
-
The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.Technol Cancer Res Treat. 2018 Jan 1;17:1533033818780063. doi: 10.1177/1533033818780063. Technol Cancer Res Treat. 2018. PMID: 29916308 Free PMC article.
-
Functional analysis, overexpression, and kinetic characterization of pyruvate kinase from methicillin-resistant Staphylococcus aureus.Biochemistry. 2010 Sep 7;49(35):7733-47. doi: 10.1021/bi100780t. Biochemistry. 2010. PMID: 20707314
-
Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents.RSC Med Chem. 2021 May 17;12(7):1121-1141. doi: 10.1039/d1md00045d. eCollection 2021 Jul 21. RSC Med Chem. 2021. PMID: 34355179 Free PMC article. Review.
References
-
- Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry. 2005;44:9417–29. - PubMed
-
- Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230–3. - PubMed
-
- Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452:181–6. - PubMed
-
- Warburg O. On the origin of cancer cells. Science. 1956;123:309–14. - PubMed
-
- Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol. 2007;5:127–36. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous